Guidelines for the treatment of psoriatic arthritis with biologics

Reference List
(1) Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I et al. Guideline for anti‐TNFalpha
therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44(3):390‐397.
(2) Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA et al. British
Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;
161(5):987‐1019.
(3) Keat A, Barkham N, Bhalla A, Gaffney K, Marzo‐Ortega H, Paul S et al. BSR guidelines for
prescribing TNF‐{alpha} blockers in adults with ankylosing spondylitis. Report of a working party of the British
Society for Rheumatology. Rheumatology (Oxford) 2005.
(4) Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M et al. BSR and BHPR
rheumatoid arthritis guidelines on safety of anti‐TNF therapies. Rheumatology (Oxford) 2010; 49(11):2217‐
2219.
Declarations of Interest
The following authors have received honoraria as speakers and/or for consultancy work and/or sponsorship to
attend meetings or their institutes have received grants from the following
Laura Coates; Abbott, Janssen Biologics, Pfizer
Philip Helliwell; Abbott, Pfizer, Cellgene, Sanofi, Bristol Myers Squib, UCB, Shering Plough, Roche
Eleanor Korendowych; Abbott, Pfizer, Shering Plough
Stuart Kyle; Abbott, Roche, Chugai Roche, MSD
Iain McInnes; Pfizer, Merck, Bristol Myers Squibb, Abbott
Susan Oliver; Abbott, Astra Zeneca, Chugai Roche, Janssen‐Cilag, Pfizer, Roche, UCB
Catherine Smith; Abbott, Janssen‐Cilag, Schering‐Plough, Wyeth/Pfizer
Neil McHugh; Abbott, Janssen‐Cilag, Wyeth, Schering‐Plough
34